Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study

PLoS Neglected Tropical Diseases

Volumn 9, Issue 10, 2015, Pages

  Diro, Ermias ^a,b   Ritmeijer, Koert ^c   Boelaert, Marleen ^b   Alves, Fabiana ^d   Mohammed, Rezika ^a   Abongomera, Charles ^c   Ravinetto, Raffaella ^b,e   De Crop, Maaike ^b   Fikre, Helina ^a   Adera, Cherinet ^c   Colebunders, Robert ^b   van Loen, Harry ^b   Menten, Joris ^b   Lynen, Lutgarde ^b   Hailu, Asrat ^f   van Griensven, Johan ^b  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d Drugs for Neglected Diseases Initiative   (Switzerland)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

PENTAMIDINE ISETHIONATE; ANTIPROTOZOAL AGENT; PENTAMIDINE;

ADULT; ARTHRALGIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPEREMIA; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; INJECTION SITE HYPERSENSITIVITY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NOSE OBSTRUCTION; OPEN STUDY; PNEUMONIA; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK FACTOR; TETANY; VIRUS LOAD; VISCERAL LEISHMANIASIS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; LEISHMANIASIS, VISCERAL; RECURRENT DISEASE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIPROTOZOAL AGENTS; COHORT STUDIES; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; MALE; PENTAMIDINE; PROSPECTIVE STUDIES; RECURRENCE;

EID: 84959107119     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004087     Document Type: Article

References (26)

1. Arce A, Estirado A, Ordobas M, Sevilla S, Garcia N, et al. (2013) Re-emergence of leishmaniasis in Spain: community outbreak in Madrid, Spain, 2009 to 2012. Euro Surveill18: 20546. 23929177
2. Lopez-Velez R, (2003) The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol97Suppl 1: 143–147. doi: 10.1179/00034980322500261514678641
3. Petter A, Shetty-Lee A, Kofler G, Huemer HP, Larcher C, (2001) Visceral leishmaniasis in an AIDS patient on successful antiretroviral therapy: failure of parasite eradication despite increase in CD4+ T-cell count but low CD8+ T-cell count. Scand J Infect Dis33: 236–238. 11303820
4. World Health Organization (2007) Report of the Fifth Consultative Meeting on Leishmania/HIV Coinfection, March 20–22, Addis Ababa, Ethiopia.
5. Monge-Maillo B, Norman FF, Cruz I, Alvar J, Lopez-Velez R, (2014) Visceral leishmaniasis and HIV coinfection in the Mediterranean region. PLoS Negl Trop Dis8: e3021. doi: 10.1371/journal.pntd.0003021 PNTD-D-13-02062 [pii]. 25144380
6. Molina R, Gradoni L, Alvar J, (2003) HIV and the transmission of Leishmania. Ann Trop Med Parasitol97Suppl 1: 29–45. doi: 10.1179/00034980322500251614678631
7. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, et al. (2003) Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol41: 5080–5084. 14605142
8. Laguna F, Adrados M, Alvar J, Soriano V, Valencia ME, et al. (1997) Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis16: 898–903. 9495670
9. Lopez-Velez R, Videla S, Marquez M, Boix V, Jimenez-Mejias ME, et al. (2004) Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother53: 540–543. doi: 10.1093/jac/dkh084 dkh084 [pii]. 14739148
10. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E, (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore)80: 54–73.
11. Ribera E, Ocana I, de OJ, Cortes E, Gasser I, et al. (1996) Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med100: 496–501. S0002934397895034 [pii]. 8644760
12. Bourgeois N, Bastien P, Reynes J, Makinson A, Rouanet I, et al. (2010) 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med11: 670–673. HIV846 [pii]; doi: 10.1111/j.1468-1293.2010.00846.x20500233
13. [Anonymous] (2014) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. T-15-T-25.
14. World Health Organization (3-22-2010) Control of the Leishmaniases. WHO Technical Report Series 949: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. Geneva, Swetzerland: World Health Organization.
15. Molina I, Falco V, Crespo M, Riera C, Ribera E, et al. (2007) Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother60: 837–842. dkm294 [pii]; doi: 10.1093/jac/dkm29417684055
16. Perez-Molina JA, Lopez-Velez R, Montilla P, Guerrero A, (1996) Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS10: 237–238. 8838721
17. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN, (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis46: 1702–1709. doi: 10.1086/58789918419422
18. Calza L, Marinacci G, Manfredi R, Colangeli V, Fortunato L, et al. (2001) Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report. J Chemother13: 653–657. 11806628
19. Patel TA, Lockwood DN, (2009) Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases. Trop Med Int Health14: 1064–1070. TMI2329 [pii]; doi: 10.1111/j.1365-3156.2009.02329.x19552658
20. [Anonymous] (2008) Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia, Federal HIV/AIDS Prevention and Control Office, Federal Ministry of Health.
21. Cota GF, de Sousa MR, Rabello A, (2011) Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis5: e1153. doi: 10.1371/journal.pntd.0001153 PNTD-D-10-00249 [pii]. 21666786
22. Dorlo TP, Kager PA, (2008) Pentamidine dosage: a base/salt confusion. PLoS Negl Trop Dis2: e225. doi: 10.1371/journal.pntd.000022518509543
23. Fenske S, Stellbrink HJ, Albrecht H, Greten H, (1991) Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment. Klin Wochenschr69: 793–796. 1662324
24. Gazapo E (2010) Visceral leishmaniasis secondary prophylaxis in HIV patients. Int Conf AIDS.
25. Matheron S, Cabie A, Parquin F, Mayaud C, Roux P, et al. (1992) Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis. AIDS6: 238–240. 1558727
26. van GJ, Diro E, Lopez-Velez R, Ritmeijer K, Boelaert M, et al. (2014) A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?PLoS Negl Trop Dis8: e3011. doi: 10.1371/journal.pntd.0003011 PNTD-D-13-02067 [pii]. 25101627